Literature DB >> 30280248

Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Marc J Gollub1, Ivana Blazic2, David D B Bates3, Naomi Campbell4, Andrea Knezevic5, Mithat Gonen5, Patricio Lynn6, Martin R Weiser7, Julio Garcia-Aguilar7, Andreas M Hötker8, Andrea Cercek9, Leonard Saltz9.   

Abstract

OBJECTIVES: To determine the appearance of rectal cancer on MRI after oxaliplatin-based chemotherapy (ICT) and make a preliminary assessment of MRI's value in predicting response to total neoadjuvant treatment (TNT).
METHODS: In this IRB-approved, HIPAA-compliant, retrospective study between 1 January 2010-20 October 2014, pre- and post-ICT tumour T2 volume, relative T2 signal intensity (rT2SI), node size, signal intensity and border characteristics were assessed in 63 patients (65 tumours) by three readers. The strength of association between the reference standard of histopathological percent tumour response and tumour volume change, rT2SI and lymph node characteristics was assessed with Spearman's correlation coefficient and Wilcoxon's rank sum test. Cox regression was used to assess association between DFS and radiological measures.
RESULTS: Change in T2 volume was not associated with TNT response. Change in rT2SI showed correlation with TNT response for one reader only using selective regions of interest (ROIs) and borderline correlation with response using total volume ROI. There was a significant negative correlation between baseline and post-ICT node size and TNT response (r = -0.25, p = 0.05; r = -0.35, p = 0.005, readers 1 and 2, respectively). Both baseline and post-induction median node sizes were significantly smaller in complete responders (p = 0.03, 0.001; readers 1 and 2, respectively). Change in largest baseline node size and decrease in post-ICT node signal heterogeneity were associated with 100% tumour response (p = 0.04). Nodal sizes at baseline and post-ICT MRI correlated with DFS.
CONCLUSION: In patients undergoing post-ICT MRI, tumour volume did not correlate with TNT response, but decreased lymph node sizes were significantly associated with complete response to TNT as well as DFS. Relative T2SI showed borderline correlation with TNT response. KEY POINTS: • MRI-based tumour volume after induction chemotherapy and before chemoradiotherapy did not correlate with overall tumour response at the end of all treatment. • Lymph node size after induction chemotherapy and before chemoradiotherapy was strongly associated with complete pathological response after all treatment. • Lymph node sizes at baseline and post-induction chemotherapy MRI correlated with disease-free survival.

Entities:  

Keywords:  Chemotherapy; MRI; Rectal cancer; Total neoadjuvant treatment

Mesh:

Substances:

Year:  2018        PMID: 30280248      PMCID: PMC6420840          DOI: 10.1007/s00330-018-5726-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

1.  Progress in the PROSPECT trial: precision treatment for rectal cancer?

Authors:  Martin R Weiser; Alessandro Fichera; Deborah Schrag; Judy C Boughey; Y Nancy You
Journal:  Bull Am Coll Surg       Date:  2015-04

2.  MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.

Authors:  U B Patel; G Brown; I Machado; J Santos-Cores; C Pericay; E Ballesteros; A Salud; M Isabel-Gil; C Montagut; J Maurel; J Ramón-Ayuso; N Martin; R Estevan; C Fernandez-Martos
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

3.  Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison.

Authors:  Gina Brown; Catherine J Richards; Michael W Bourne; Robert G Newcombe; Andrew G Radcliffe; Nicholas S Dallimore; Geraint T Williams
Journal:  Radiology       Date:  2003-05       Impact factor: 11.105

4.  High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size?

Authors:  Joo Hee Kim; Geerard L Beets; Myeong-Jin Kim; Alfons G H Kessels; Regina G H Beets-Tan
Journal:  Eur J Radiol       Date:  2004-10       Impact factor: 3.528

5.  Neoadjuvant chemotherapy evaluation by MRI volumetry in rectal cancer followed by chemoradiation and total mesorectal excision: Initial experience.

Authors:  Stephanie Nougaret; Shinya Fujii; Helen C Addley; Frederic Bibeau; Himanshu Pandey; Hisham Mikhael; Caroline Reinhold; David Azria; Philippe Rouanet; Benoit Gallix
Journal:  J Magn Reson Imaging       Date:  2012-11-13       Impact factor: 4.813

6.  MRI and Diffusion-weighted MRI Volumetry for Identification of Complete Tumor Responders After Preoperative Chemoradiotherapy in Patients With Rectal Cancer: A Bi-institutional Validation Study.

Authors:  Doenja M J Lambregts; Sheng-Xiang Rao; Sander Sassen; Milou H Martens; Luc A Heijnen; Jeroen Buijsen; Meindert Sosef; Geerard L Beets; Roy A Vliegen; Regina G H Beets-Tan
Journal:  Ann Surg       Date:  2015-12       Impact factor: 12.969

7.  Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters.

Authors:  Andreas M Hötker; Lisa Tarlinton; Yousef Mazaheri; Kaitlin M Woo; Mithat Gönen; Leonard B Saltz; Karyn A Goodman; Julio Garcia-Aguilar; Marc J Gollub
Journal:  Eur Radiol       Date:  2016-03-05       Impact factor: 5.315

8.  Quantitative Assessment of Rectal Cancer Response to Neoadjuvant Combined Chemotherapy and Radiation Therapy: Comparison of Three Methods of Positioning Region of Interest for ADC Measurements at Diffusion-weighted MR Imaging.

Authors:  Ivana M Blazic; Gordana B Lilic; Milan M Gajic
Journal:  Radiology       Date:  2016-06-02       Impact factor: 11.105

9.  Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy.

Authors:  Brunella Barbaro; Cecilia Fiorucci; Carmen Tebala; Vincenzo Valentini; Maria Antonietta Gambacorta; Fabio Maria Vecchio; Gianluca Rizzo; Claudio Coco; Antonio Crucitti; Carlo Ratto; Lorenzo Bonomo
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

10.  PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.

Authors:  F Sclafani; G Brown; D Cunningham; A Wotherspoon; D Tait; C Peckitt; J Evans; S Yu; L Sena Teixeira Mendes; J Tabernero; B Glimelius; A Cervantes; J Thomas; R Begum; J Oates; I Chau
Journal:  Ann Oncol       Date:  2016-05-23       Impact factor: 32.976

View more
  4 in total

Review 1.  Current controversy, confusion, and imprecision in the use and interpretation of rectal MRI.

Authors:  Marc J Gollub; Chandana Lall; Neeraj Lalwani; Michael H Rosenthal
Journal:  Abdom Radiol (NY)       Date:  2019-11

2.  Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence.

Authors:  Karen Benezery; Lucile Montagne; Ludovic Evesque; Renaud Schiappa; Jean-Michel Hannoun-Levi; Eric Francois; Brice Thamphya; Jean-Pierre Gerard
Journal:  Clin Transl Radiat Oncol       Date:  2020-07-06

Review 3.  Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples.

Authors:  Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello
Journal:  Abdom Radiol (NY)       Date:  2020-10-28

4.  Predicting Response to Total Neoadjuvant Treatment (TNT) in Locally Advanced Rectal Cancer Based on Multiparametric Magnetic Resonance Imaging: A Retrospective Study.

Authors:  Ganlu Ouyang; Xibiao Yang; Xiangbing Deng; Wenjian Meng; Yongyang Yu; Bing Wu; Dan Jiang; Pei Shu; Ziqiang Wang; Jin Yao; Xin Wang
Journal:  Cancer Manag Res       Date:  2021-07-13       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.